MedDataX Logo

A Multi-center, Retrospective Analysis of Clinical Character, Outcome and Prognosis of Lymphoepithelioma-like Carcinoma

NCT ID: NCT04614818

Last Updated: 2020-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators retrospective collect the clinical data of patients diagnosed with lymphoepithelioma-like carcinoma, including primary site, gender, age, smoking history, tumor stage, time of initial treatment, EBV-DNA copy number, first-line treatment and survival status.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lymphoepithelioma-like carcinoma (LELC) is a rare EBV-related tumor. Its histology is similar to that of nasopharyngeal carcinoma. In 2004, the WHO classified LELC into one subtype of large cell carcinoma, and the 2015 WHO classified it as other and unclassified cancers. LELC can originate in many organs, including parotid glands, throat, lungs, digestive tract, genitourinary system, etc. Driver gene mutations are rarely seen, and most of them are PD-L1 positive. In terms of treatment, there is no standard first-line treatment for lymphoepithelioma-like cancer. Patients with early-stage lymphoepithelioma-like cancer can receive surgery or radiotherapy, while palliative radiotherapy or chemotherapy is the main treatment for patients in advanced stage. The survival time is about 107 months, the 5-year OS is 59.5%, which is better than the prognosis of lung squamous cell carcinoma in the same period. A retrospective study of Sun yat-sen University Cancer Hospital included 127 patients with advanced lung LELC who received first-line chemotherapy between 2007 and 2018. Gemcitabine and platinum based chemotherapy and paclitaxel and platinum based regimens are significantly better than pemetrexed and platinum, but most of the current studies on lymphoepithelioma-like cancer focus on LELC that originates in the lung. But for other sites, such as parotid glands, liver, digestive tract, are mostly based on case reports, and there are few retrospective studies with large samples to explore their clinical features and treatment outcome. Therefore, investigators designed this retrospective clinical study to analyze the clinical characteristics, treatment, survival, and prognostic risk factors of patients with lymphoepithelioma-like carcinoma in order to summary the clinical character and guide treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoepithelioma-Like Carcinoma Lymphoepithelioma-Like Carcinoma of Thymus Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pulmonary lymphoepithelioma-like carcinoma

The primary site of lymphoepithelioma-like carcinoma locates in the lungs.

Non-intervention research

Intervention Type OTHER

Non-intervention research

lymphoepithelioma-like carcinoma of thymus

The primary site of lymphoepithelioma-like carcinoma locates in the thymus.

Non-intervention research

Intervention Type OTHER

Non-intervention research

lymphoepithelioma-like carcinoma of salivary glands

The primary site of lymphoepithelioma-like carcinoma locates in the parotid gland or submandibular gland.

Non-intervention research

Intervention Type OTHER

Non-intervention research

lymphoepithelioma-like carcinoma of stomach

The primary site of lymphoepithelioma-like carcinoma locates in the stomach.

Non-intervention research

Intervention Type OTHER

Non-intervention research

lymphoepithelioma-like carcinoma of esophagus

The primary site of lymphoepithelioma-like carcinoma locates in the esophagus.

Non-intervention research

Intervention Type OTHER

Non-intervention research

lymphoepithelioma-like carcinoma of liver

The primary site of lymphoepithelioma-like carcinoma locates in the liver.

Non-intervention research

Intervention Type OTHER

Non-intervention research

lymphoepithelioma-like carcinoma of ovaries

The primary site of lymphoepithelioma-like carcinoma locates in the ovaries.

Non-intervention research

Intervention Type OTHER

Non-intervention research

lymphoepithelioma-like carcinoma of cervix

The primary site of lymphoepithelioma-like carcinoma locates in the cervix.

Non-intervention research

Intervention Type OTHER

Non-intervention research

lymphoepithelioma-like carcinoma of tonsil

The primary site of lymphoepithelioma-like carcinoma locates in the tonsil.

Non-intervention research

Intervention Type OTHER

Non-intervention research

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-intervention research

Non-intervention research

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Lymphoepithelioma-like carcinoma confirmed by histopathology;
* 2\. The primary lesion does not involve the nasopharynx;
* 3\. Complete data for patient's character, laboratory and imaging test, treatment and follow-up are available.

Exclusion Criteria

* 1\. Concomitant with other tumor components at the time of diagnosis;
* 2\. Have a history of any other malignant tumors;
* 3\. Lack of complete data
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sun Yat-sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tongyu Lin

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sun yat-sen University Cancer Center

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mei-ting Chen, Doctor

Role: primary

[email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Wu Q, Wang W, Zhou P, Fu Y, Zhang Y, Shao YW, Jiang L. Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden. Pathol Res Pract. 2020 Aug;216(8):153043. doi: 10.1016/j.prp.2020.153043. Epub 2020 Jun 2.

Reference Type BACKGROUND
PMID: 32703503 (View on PubMed)

Fang W, Hong S, Chen N, He X, Zhan J, Qin T, Zhou T, Hu Z, Ma Y, Zhao Y, Tian Y, Yang Y, Xue C, Tang Y, Huang Y, Zhao H, Zhang L. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget. 2015 Oct 20;6(32):33019-32. doi: 10.18632/oncotarget.5028.

Reference Type BACKGROUND
PMID: 26361045 (View on PubMed)

He J, Shen J, Pan H, Huang J, Liang W, He J. Pulmonary lymphoepithelioma-like carcinoma: a Surveillance, Epidemiology, and End Results database analysis. J Thorac Dis. 2015 Dec;7(12):2330-8. doi: 10.3978/j.issn.2072-1439.2015.12.62.

Reference Type BACKGROUND
PMID: 26793355 (View on PubMed)

Abouelfad DM, Yassen NN, Amin HAA, Shabana ME. Lymphoepithelioma-Like Carcinoma of the Breast Mimicking Granulomatous Mastitis- Case Report and Review of the Literature. Asian Pac J Cancer Prev. 2017 Jul 27;18(7):1737-1741. doi: 10.22034/APJCP.2017.18.7.1737.

Reference Type BACKGROUND
PMID: 28749097 (View on PubMed)

Chen M, Chen Y, Fang X, Wang Z, Pu X, Liang C, Guo H, Li Q, Pan F, Hong H, Huang H, Li J, Lin T. Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study. BMC Pulm Med. 2022 Sep 22;22(1):360. doi: 10.1186/s12890-022-02097-6.

Reference Type DERIVED
PMID: 36138362 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B2020-289-01

Identifier Type: -

Identifier Source: org_study_id